drugset / Trial / NCT02802228

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

NCT02802228 ↗

Phase 2 Completed 30 enrolled Cumberland Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This placebo-controlled study will assess the safety and efficacy of a 90-day course of treatment with ifetroban for portal hypertension in cirrhotic patients

Timeline

Start
2017-03-06
Primary completion
2018-07-17
Completion
2018-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Ifetroban Small molecule — Intravenous